---
title: "Taysha Gene Therapies grants new hire 144,000 RSUs, 92,400 stock options priced at $5.78"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295231450.md"
description: "Taysha Gene Therapies granted a new employee 144,000 Restricted Stock Units (RSUs) and stock options for 92,400 shares under its 2023 Inducement Plan. The RSUs vest in four equal annual installments starting after one year. The options have a $5.78 exercise price, a 10-year term, and vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the next three years."
datetime: "2026-08-07T12:02:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295231450.md)
  - [en](https://longbridge.com/en/news/295231450.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295231450.md)
generator: "portal-rs"
---

# Taysha Gene Therapies grants new hire 144,000 RSUs, 92,400 stock options priced at $5.78

-   Taysha Gene Therapies granted a new employee 144,000 RSUs plus stock options for 92,400 shares under its 2023 Inducement Plan. \* RSUs vest in four equal annual installments starting on the first anniversary, subject to continued service. \* Options carry a $5.78 exercise price, a 10-year term, vesting over four years with 25% after one year. \* Remaining 75% of the options vest in equal monthly installments over the next 36 months, subject to continued service. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Taysha Gene Therapies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608070800PRIMZONEFULLFEED9804842) on August 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [TSHA.US](https://longbridge.com/en/quote/TSHA.US.md)

## Related News & Research

- [Taysha Gene Therapies Q2 net loss widens on higher R&D costs](https://longbridge.com/en/news/295573772.md)
- [Taysha Gene Therapies taps Catalent for TSHA-102 Rett syndrome commercial manufacturing support](https://longbridge.com/en/news/294689795.md)
- [ADM announces Q3 2026 distribution of R$ 0.22 per unit, payable Sept. 15](https://longbridge.com/en/news/296399586.md)
- [Signaux Girod reports 1,032,500 shares outstanding, 1,051,466 theoretical voting rights as of July 31](https://longbridge.com/en/news/296448329.md)
- [XCharge plans 1-for-20 reverse ADS split via ratio change effective Aug. 21](https://longbridge.com/en/news/296347969.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**